SCHEMBL278443

SCHEMBL278443

CC(=O)OC[C@H]1OC(n2cnc3c(Cl)nc(N)nc32)[C@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.84
ALDH1A1 P00352 2/20 0.84
TP53 P04637 2/20 0.84
MAPT P10636 1/20 0.84
TDP1 Q9NUW8 1/20 0.84
ACHE P22303 5/20 0.53
PRKAB2 O43741 1/20 0.53
PRKAG1 P54619 1/20 0.53
PRKAA2 P54646 1/20 0.53
PRKAA1 Q13131 1/20 0.53
PRKAG3 Q9UGI9 1/20 0.53
PRKAG2 Q9UGJ0 1/20 0.53
PRKAB1 Q9Y478 1/20 0.53
NT5E P21589 2/20 0.52
HINT1 P49773 2/20 0.49
THRB P10828 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HIF1A Q16665 1/20 0.46
ADORA3 P0DMS8 1/20 0.43
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1120550 1.00 LMNA (0.84) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL3478703 1.00 LMNA (0.84) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL1120556 1.00 LMNA (0.84) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL1120553 1.00 LMNA (0.84) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL313898 1.00 LMNA (0.84) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL13924747 1.00 LMNA (0.84) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL13296259 1.00 LMNA (0.84) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL3427712 1.00 LMNA (0.84) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL6363586 0.95 LMNA (0.76) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL17198377 0.93 ALDH1A1 (0.73) LMNAALDH1A1TP53MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47351-E1 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists GILEAD SCIENCES, INC. (US) 2019-04-16 US disclosed
US-9289446-B2 Myocardial perfusion imaging methods and compositions GILEAD SCIENCES, INC. (US) 2016-03-22 US disclosed
US-20150283162-A1 MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS GILEAD PALO ALTO, INC. 2015-10-08 US disclosed
US-9045519-B2 N-pyrazole A2A receptor agonists GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8906878-B2 Myocardial perfusion imaging methods and compositions GILEAD SCIENCES, INC. (US) 2014-12-09 US disclosed
US-20140073596-A1 N-Pyrazole A2A Receptor Agonists GILEAD SCIENCES, INC. (US) 2014-03-13 US disclosed
US-8569260-B2 N-pyrazole A2A receptor agonists GILEAD SCIENCES, INC. (US) 2013-10-29 US disclosed
US-8470801-B2 Myocardial perfusion imaging methods and compositions GILEAD SCIENCES, INC. (US) 2013-06-25 US disclosed
US-20130058866-A1 N-PYRAZOLE A2A RECEPTOR AGONISTS GILEAD SCIENCES, INC. 2013-03-07 US disclosed
US-8278435-B2 N-pyrazole A2A receptor agonists GILEAD SCIENCES, INC. (US) 2012-10-02 US disclosed
US-20070207978-A1 C-Pyrazole A2A receptor agonists CV THERAPEUTICS, INC. 2007-09-06 US disclosed
US-20070207978-A1 C-Pyrazole A2A receptor agonists CV THERAPEUTICS, INC. 2007-09-06 US disclosed
US-20070203090-A1 N-pyrazole A2A receptor agonists CV THERAPEUTICS, INC. 2007-08-30 US disclosed
US-7183264-B2 N-pyrazole A2A receptor agonists CV THERAPEUTICS, INC. (US) 2007-02-27 US disclosed
US-7183264-B2 N-pyrazole A2A receptor agonists CV THERAPEUTICS, INC. (US) 2007-02-27 US disclosed
US-20060052332-A1 N-pyrazole A2A receptor agonists CV THERAPEUTICS, INC. 2006-03-09 US disclosed
EP-1446413-A1 SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES King Pharmaceuticals Research and Development Inc. (US) 2004-08-18 EP disclosed
US-20040038928-A1 N-pyrazole A2A receptor agonists CV THERAPEUTICS, INC. 2004-02-26 US disclosed
EP-1194441-B1 A2A RECEPTOR AGONISTS CV THERAPEUTICS INC (US) 2003-10-22 EP disclosed
WO-2003035662-A1 SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150283162-A1 MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS ADORA2A, ADORA3, ADORA1 LMNA 1298/4885ALDH1A1 1336/4885TP53 2068/4885
US-20040038928-A1 N-pyrazole A2A receptor agonists ADORA2A, ADORA3, ADORA1 LMNA 3308/4885ALDH1A1 1118/4885TP53 4170/4885
US-20140073596-A1 N-Pyrazole A2A Receptor Agonists ADORA2A, ADORA3, TBXA2R LMNA 3247/4885ALDH1A1 1264/4885TP53 4204/4885
US-20060052332-A1 N-pyrazole A2A receptor agonists ADORA2A, ADORA3, TBXA2R LMNA 3247/4885ALDH1A1 1264/4885TP53 4204/4885
US-20070207978-A1 C-Pyrazole A2A receptor agonists ADORA2A, ADORA3, TBXA2R LMNA 2553/4885ALDH1A1 1002/4885TP53 4377/4885
US-20130058866-A1 N-PYRAZOLE A2A RECEPTOR AGONISTS ADORA2A, ADORA3, TBXA2R LMNA 3247/4885ALDH1A1 1264/4885TP53 4204/4885
US-20070203090-A1 N-pyrazole A2A receptor agonists ADORA2A, ADORA3, TBXA2R LMNA 3247/4885ALDH1A1 1264/4885TP53 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.